


DUAL GLUCAGON AGONIST; GLP-1 AGONIST
ACTIVE SUBSTANCE: 10 MG SURVODUTIDE
FORM: 2 ML VIAL
ACTIVE HALF-LIFE: 109-115 HOURS
DOSAGE: MEN 0.6-4.8 MG/WEEK
ACNE: PERHAPS
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HBP): NO
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: DRAGON PHARMA, EUROPE
LABORATORY TESTED: VIEW LAB RESULTS
DragonPharma.Net offers genuine peptides from Dragon Pharma. Each 2 mL vial of Survodutide delivers a clinical-grade 10 mg dose of this advanced GLP-1 and glucagon receptor dual agonist.
Survodutide is a next-generation peptide therapeutic engineered by Dragon Pharma to support fat loss, appetite regulation, and metabolic health. As a dual agonist of the GLP-1 and glucagon receptors, it enhances energy expenditure while reducing hunger signals, making it highly effective for individuals managing obesity, metabolic syndrome, or insulin resistance.
Learn more about Survodutide's mechanism of action and its clinical development path.
Administered via weekly subcutaneous injections, Survodutide is typically started at a low dose and titrated upwards over several weeks. This approach minimizes gastrointestinal discomfort while achieving optimal metabolic outcomes. Typical protocols escalate from 0.6 mg/week up to 4.8 mg/week across a 16–20 week ramp-up phase, followed by a maintenance cycle.
Dosage schedules should be individualized and supervised by a medical professional, especially for patients with comorbidities.
A standard example cycle begins with:
Clinical benefits are most notable when Survodutide is paired with a caloric deficit and light physical activity.
Survodutide is well tolerated by most users. Initial side effects can include fatigue, mild dizziness, and gastrointestinal symptoms such as nausea or bloating. These effects usually subside as the body adapts.
More serious side effects are rare but may include kidney strain or cardiovascular impacts in predisposed individuals. Periodic lab monitoring is advised, especially during prolonged use cycles.
Survodutide may be a strong addition to any advanced fat-loss protocol. It's ideal for users looking to amplify body recomposition or support weight control where traditional strategies fall short.
Survodutide is available in our GLP-1 agonists category, alongside other peptides designed to enhance fat metabolism and appetite regulation.
Dragon Pharma is known for delivering research-backed peptides with high purity and consistent dosing. Whether you're an athlete cutting for a show or managing long-term weight loss, this is one of the most potent metabolic enhancers on the market.
Browse more Dragon Pharma gear trusted by athletes and biohackers worldwide.
Survodutide by Dragon Pharma is designed to reduce appetite and increase energy usage by activating GLP-1 and glucagon receptors. This dual action helps promote fat loss and improve metabolic health.
Start with a low dose (0.6 mg weekly), then gradually increase up to 4.8 mg over several weeks. Survodutide is injected subcutaneously once per week. Always follow professional medical advice for dosage and cycle length.
Survodutide is well tolerated by most users, especially when dosed correctly. Side effects like nausea or dizziness are possible early in the cycle, but these often subside. Monitoring is important, especially for kidney and heart function.
Common side effects include gastrointestinal discomfort, nausea, vomiting, dizziness, and fatigue. Most symptoms fade as the body adapts. Serious effects are rare but possible in individuals with pre-existing health issues.
You can purchase original Dragon Pharma Survodutide 10 mg from our secure online store. All products are shipped discreetly across the USA and come with verified lab results.
Please log in to write SURVODUTIDE 10 MG review.
CLASSIFICATION: GLP-1 RECEPTOR AGONIST
ACTIVE SUBSTANCE: SEMAGLUTIDE
FORM: LYOPHILIZED POWDER – 2 ML VIAL (5 MG/VIAL)
ACTIVE HALF-LIFE: ~7 DAYS
DOSAGE: 0.25 - 0.5 MG/WEEK
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HIGH BLOOD PRESSURE (HBP)): NO
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: DRAGON PHARMA, EUROPE
LABORATORY TESTED: VIEW LAB RESULTS
CLASSIFICATION: HUMAN PEPTIDE HORMONE
ACTIVE SUBSTANCE: GHK-CU
FORM: 2 ML VIAL x 10 MG
ACTIVE HALF-LIFE: ~ 30 MINUTES
DOSAGE: 2-3 TIMES PER WEEK
ACNE: NOT REPORTED
WATER RETENTION: NONE
HIGH BLOOD PRESSURE (HBP): NO KNOWN IMPACT
HEPATOTOXICITY: NONE
AROMATIZATION: DOES NOT AROMATIZE
MANUFACTURER: DRAGON PHARMA
CLASSIFICATION: FAT-BURNING PEPTIDE (GH FRAGMENT)
ACTIVE SUBSTANCE: AOD9604 (Fragment 176-191)
FORM: 2 mL VIAL × 5 MG
ACTIVE HALF-LIFE: ~4 HOURS
DOSAGE: MEN/WOMEN – 300–500 MCG/DAY
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HBP): NO
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: DRAGON PHARMA
CLASSIFICATION: GIP/GLP-1/GLUCAGON RECEPTOR TRIAGONIST
ACTIVE SUBSTANCE: RETATRUTIDE
FORM: 2 ML VIAL x 10 MG
ACTIVE HALF-LIFE: ~ 6 DAYS
DOSAGE: 0.5 MG/WEEK
ACNE: N/A
WATER RETENTION: N/A
HIGH BLOOD PRESSURE (HBP): N/A
HEPATOTOXICITY: N/A
AROMATIZATION: N/A
MANUFACTURER: DRAGON PHARMA
LABORATORY TESTED: VIEW LAB RESULTS
CLASSIFICATION: GLP-1 RECEPTOR AGONIST
ACTIVE SUBSTANCE: TIRZEPATIDE
FORM: LYOPHILIZED POWDER – 2 ML VIAL (5 MG/VIAL)
ACTIVE HALF-LIFE: ~5 DAYS
DOSAGE: 2.5 - 5 MG/WEEK (RESEARCH USE ONLY)
ACNE: NO
WATER RETENTION: NO
HIGH BLOOD PRESSURE (HIGH BLOOD PRESSURE (HBP)): NO
HEPATOTOXICITY: NO
AROMATIZATION: NO
MANUFACTURER: DRAGON PHARMA, EUROPE
LABORATORY TESTED: VIEW LAB RESULTS
Nov 23, 2024 (10:11)
Legit stuff that delivers fast results